Caribou Biosciences to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU) said management will attend two investor conferences in February–March 2026. Key engagements include a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Feb 19, 2026 at 10:45 AM ET and a fireside chat at the Leerink Global Healthcare Conference in Miami on Mar 10, 2026 at 8:00 AM ET.
A webcast of the Leerink presentation will be available via the company Events page and accessible for at least 30 days after the event.
Details
News Market Reaction – CRBU
On Feb 13, the first trading day after this news, CRBU closed 3.95% above the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:
- Citi 2026 Virtual Oncology Leadership Summit, Virtual
February 19, 2026, with a fireside chat at 10:45 AM ET
- Leerink Global Healthcare Conference, Miami, FL
March 10, 2026, with a fireside chat at 8:00 AM ET
Webcast
For more information and link to the Leerink webcast, please visit the Events page on Caribou’s website. The webcast will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the Company @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.